2023
Long-term PCI outcomes in chronic versus acute coronary syndromes: 5-year results of the TARGET All Comers trial
Patel K, Lansky A, Kelbaek H, Xu B, Van Royen N, Johnson T, Anderson R, Wijns W, Baumbach A. Long-term PCI outcomes in chronic versus acute coronary syndromes: 5-year results of the TARGET All Comers trial. European Heart Journal 2023, 44: ehad655.1494. DOI: 10.1093/eurheartj/ehad655.1494.Peer-Reviewed Original ResearchAcute coronary syndromeChronic coronary syndromeProbable stent thrombosisCoronary syndromeStent thrombosisFIREHAWK stentLesion failureClinical presentationLong-term PCI outcomesPatient-oriented composite endpointTarget lesion revascularisationMajor adverse eventsLong-term outcomesLong-term safetyCCS cohortComer patientsID-TLRLesion revascularisationCCS patientsOpen labelAdverse eventsBaseline characteristicsACS cohortComposite endpointComers trial
2021
TCT-489 Three-Year Outcomes of Patients Treated With the Firehawk Stent Versus XIENCE Stent on the Basis of Diabetes Status: Subgroup Analysis of the TARGET All Comers Trial
Hussain Y, Wijns W, Xu B, Kelbæk H, Knaapen P, Zheng M, Slagboom T, Johnson T, Smits P, Arkenbout K, Holmvang L, Janssens L, Ochala A, Brugaletta S, Schmitz T, Anderson R, Rittger H, Berti S, Barbato E, Toth G, Maillard L, Valina C, Buszman P, Thiele H, Schachinger V, Baumbach A, Lansky A. TCT-489 Three-Year Outcomes of Patients Treated With the Firehawk Stent Versus XIENCE Stent on the Basis of Diabetes Status: Subgroup Analysis of the TARGET All Comers Trial. Journal Of The American College Of Cardiology 2021, 78: b200. DOI: 10.1016/j.jacc.2021.09.1342.Peer-Reviewed Original Research
2018
TCT-624 A prospective multicenter randomized post-market trial evaluating a novel Cobalt Chrome Rapamycin Drug Eluting Stent: Subgroup Analysis of the TARGET All Comers Trial
Lansky A, Wijns W, Xu B, Kelbaek H, van Royen N, Zheng M, Artus-Jacenko L, Knaapen P, Slagboom T, Vlachojannis G, Arkenbout K, Holmvang L, Janssens L, Ochala A, Brugaletta S, Bruder O, Berti S, Barbato E, Toth G, Maillard L, Valina C, Buszman P, Johnson T, Thiele H, Baumbach A. TCT-624 A prospective multicenter randomized post-market trial evaluating a novel Cobalt Chrome Rapamycin Drug Eluting Stent: Subgroup Analysis of the TARGET All Comers Trial. Journal Of The American College Of Cardiology 2018, 72: b249-b250. DOI: 10.1016/j.jacc.2018.08.1826.Peer-Reviewed Original Research